Tumor progression to the metastatic state involves structural modifications in DNA markedly different from those associated with primary tumor formation

被引:26
|
作者
Malins, DC
Polissar, NL
Gunselman, SJ
机构
[1] MT WHISPER LIGHT STATIST CONSULTING,SEATTLE,WA 98122
[2] UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195
关键词
breast cancer; tumor metastasis; DNA damage; free radicals; Fourier transform-infrared spectroscopy;
D O I
10.1073/pnas.93.24.14047
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Wavenumber-absorbance relationships of infrared spectra of DNA analyzed by principal components analysis may be expressed as points in space. Each point represents a highly discriminating measure of DNA structure. Structural modifications of DNA, such as those induced by free radicals, alter vibrational and rotational motion and consequently change the spatial location of the points, Using this technology to analyze breast tumor DNA, we revealed a 94 degrees difference in direction between the progression of normal DNA --> primary tumor DNA and the progression of primary tumor DNA --> metastatic tumor DNA (P < 0.001), This sharp directional change was accompanied by a substantial increase in the structural diversity of the metastatic tumor DNA (P = 0.003), which, on the basis of the volume of the core cluster of points, could comprise as many as 11 x 10(9) different phenotypes, This suggests that the heterogeneity and varied physiological properties known to characterize malignant tumor cell populations may at least partially arise from these diverse phenotypes. The evidence suggests that the progression to the metastatic state involves structural modifications in DNA that are markedly different from the modifications associated with the formation of the primary tumor. Overall, the findings of this and earlier studies imply that the observed DNA alterations are a pivotal factor in the etiology of breast cancer and a formidable barrier to overcome in intervention to control the disease, In terms of cancer etiology and prediction, the technology described has potentially wide application to studies in which the structural status of DNA is an important consideration.
引用
收藏
页码:14047 / 14052
页数:6
相关论文
共 33 条
  • [21] Plasma cell-free DNA from metastatic gastroenteropancreatic neuroendocrine neoplasms contains tumor-associated copy number alterations
    Boons, G.
    Vandamme, T.
    Lybaert, W.
    Roeyen, G.
    Rondou, T.
    Papadimitriou, K.
    Janssens, K.
    Demey, W.
    Dero, I
    Van Camp, G.
    Peeters, M.
    Op de Beeck, K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 34 - 34
  • [22] OROTIC-ACID, A LIVER-TUMOR PROMOTER INDUCES ALTERATIONS IN LIVER DNA WHICH APPEAR TO BE DIFFERENT FROM THOSE INDUCED BY TYPICAL CARCINOGENS
    PARODI, S
    BALBI, C
    RONER, R
    PALA, M
    TANINGHER, M
    DEANGELI, MT
    RAO, PM
    RAJALAKSHMI, S
    SARMA, DSR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 104 - 104
  • [23] Integrative analysis of DNA copy number and gene expression in metastatic tumor cells from oral squamous cell carcinoma for the identification of genes associated with survival
    Xu, Chang
    Liu, Yan
    Wang, Pei
    Fan, Wenhong
    Rue, Tessa C.
    Upton, Melissa P.
    Houck, John R.
    Lohavanichbutr, Pawadee
    Doody, David R.
    Futran, Neal D.
    Zhao, Lue P.
    Schwartz, Stephen M.
    Chen, Chu
    Mendez, Eduardo
    CANCER RESEARCH, 2010, 70
  • [24] DELAYED PRESENTATION, ADVANCED AND METASTATIC DISEASE ARE ASSOCIATED WITH POOR OUTCOMES IN PRIMARY PEDIATRIC LIVER TUMOR-HEPATOBLASTOMA- STUDY FROM TERTIARY CARE HOSPITAL IN PAKISTAN
    Rehman, Palwasha
    Aslam, Sophia
    Shaheen, Najma
    Saeed, Haleema
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S271 - S271
  • [25] Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene:: More common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression
    Pulling, LC
    Divine, KK
    Klinge, DM
    Gilliland, FD
    Kang, T
    Schwartz, AG
    Bocklage, TJ
    Belinsky, SA
    CANCER RESEARCH, 2003, 63 (16) : 4842 - 4848
  • [26] Identification of p53 Mutation in Whole Genome DNA from Single Circulating Tumor Cells (CTCs) and Primary Breast Cancers (BC) from Patients (pts) with Metastatic Breast Cancer (MBC).
    Yang, L.
    Wang, Y.
    Chu, P.
    Liu, Q.
    Hsieh, B.
    Liu, X.
    Yen, Y.
    Bruce, R.
    Somlo, G.
    CANCER RESEARCH, 2011, 71
  • [27] Prolonged time to clearance of circulating-tumor DNA from patients with limited-stage small-cell lung cancer is associated with inferior progression-free and overall survival
    Cann, Christopher
    Kopparapu, Prasad
    Yan, Yingjun
    Muterspaugh, Anel
    Chen, Heidi
    Zhao, Zhiguo
    York, Sally
    Horn, Leora
    Ancell, Kristen
    Wyman, Kenneth
    Bertucci, Caterina
    Shaffer, Tristan
    Hodson, Lauren
    Garg, Kavita
    Hosseini, Seyed Ali
    Lim, Lee
    Lovly, Christine M.
    Iams, Wade
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 79 - 79
  • [28] Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).
    Goodall, Jane
    Assaf, Zoe June
    Shi, Zhen
    Seed, George
    Zhang, Liangxuan
    Lauffer, Ben
    Yuan, Wei
    Wongchenko, Matthew
    Oliveira, Flavia
    Carreira, Suzanne
    Gendreau, Steven
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Malignant and non-malignant cells from primary tumor and lymph node metastasis ecosystems show different behavior for patient-associated protein signatures in head and neck cancer
    Busso-Lopes, Ariane F.
    Rivera, Cesar
    Mello, Barbara P.
    Villa, Luisa L.
    Gonzalez-Arriagada, Wilfredo
    Paes Leme, Adriana F.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial
    Wang, Yu
    Li, Jun
    Baden, Jonathan
    Gupta, Saurabh
    David, Justin M.
    CANCER RESEARCH, 2023, 83 (07)